New safety information
Posted 11 months ago
There is a risk of necrotising fasciitis of the perineum (Fournier’s gangrene) with the SGLT2 inhibitor class issued by AstraZeneca, Boehringer Ingelheim and Merck Sharp & Dohme.
Click here to read the joint safety commuincation for more details.
Any questions regarding this communication, should be kindly directed to the relevant company contact points.